For the quarter ended December 2025, Collegium Pharmaceutical (COLL) reported revenue of $205.45 million, up 12.9% over the same period last year. EPS came in at $2.04, compared to $1.77 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $208.65 million, representing a surprise of -1.53%. The company delivered an EPS surprise of -6.99%, with the consensus EPS estimate being $2.19.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total product revenues- Belbuca: $59.14 million versus the three-analyst average estimate of $58.03 million. The reported number represents a year-over-year change of +7.1%.
- Total product revenues- Xtampza ER: $48.58 million versus the three-analyst average estimate of $51.37 million. The reported number represents a year-over-year change of -5.6%.
- Total product revenues- Symproic: $3.89 million compared to the $3.53 million average estimate based on three analysts. The reported number represents a change of -8.6% year over year.
- Total product revenues- Nucynta: $47.95 million compared to the $49.47 million average estimate based on three analysts. The reported number represents a change of +14.8% year over year.
- Total product revenues- Jornay PM: $45.89 million compared to the $46.46 million average estimate based on three analysts.
View all Key Company Metrics for Collegium Pharmaceutical here>>>
Shares of Collegium Pharmaceutical have returned +2.1% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
